Shire buys U.S.-based Foresight Biotherapeutics Inc for $300 mln
Tuesday, August 04, 2015
Pharmaceuticals company Shire Plc said it had bought New York-based Foresight Biotherapeutics Inc for $300 million, gaining access to a late-stage therapy being developed for the treatment of infectious conjunctivitis known as pink eye.
The deal gives Shire access to the global rights to FST-100, which has the potential to become the first agent to treat both viral and bacterial conjunctivitis.
reuters.com
